Figure 4.

HS-276 reduces the clinical arthritis score. DBA/1 mice induced with CIA demonstrated clinical arthritic scores around day 25, which persisted throughout the study. Mice were initially treated daily (days 21–26) with vehicle control or HS-276 (50 mg/kg IP), followed by Q2D (days 27–36). (a) Disease incidence over time in vehicle (black)- and HS-276 treated (blue) (N =12 ± SEM). (b) HS-276-treated mice show a reduction in clinical arthritic score compared to vehicle control (N =12 ± SEM). (c) Area under the curve calculation of vehicle- and HS-276-treated animals. (d) Representative photomicrographs of the forepaw, knee, and ankle from disease control (naïve)-, diseased vehicle-, and HS-276-treated animals. W identifies the wrist, arrows identify representative affected joints, and S identifies inflammation. (e) HS-276 reduced inflammation, pannus, cartilage damage (CD), bone resorption (BR), and periosteal bone formation (PBF) histological manifestations of CIA 36 days post disease onset. N =12 per group ± SEM. *p < 0.05; ***p < 0.001.